TY - JOUR
T1 - Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury
AU - Drug-Induced Liver Injury Network
AU - Vuppalanchi, Raj
AU - Bonkovsky, Herbert L.
AU - Ahmad, Jawad
AU - Barnhart, Huiman
AU - Durazo, Francisco
AU - Fontana, Robert J.
AU - Gu, Jiezhun
AU - Khan, Ikhlas
AU - Kleiner, David E.
AU - Koh, Christopher
AU - Rockey, Don C.
AU - Phillips, Elizabeth J.
AU - Li, Yi Ju
AU - Serrano, Jose
AU - Stolz, Andrew
AU - Tillmann, Hans L.
AU - Seeff, Leonard B.
AU - Hoofnagle, Jay H.
AU - Navarro, Victor J.
N1 - Funding Information:
Funding Supported as a Cooperative Agreement by National Institute of Diabetes and Digestive and Kidney Diseases with support from the Intramural Division of the National Cancer Institute , National Institutes of Health , Bethesda, MD (to the Drug-induced Liver Injury Network [ https://dilin.dcri.duke.edu/ ]): U01-DK065176 and U24-DK065176 ( Duke University ), U01-DK065211 ( Indiana University ), U01-DK065201 ( University of North Carolina ), U01-DK065184 ( University of Michigan ), U01-DK065193 ( University of Connecticut ), U01-DK065238 ( University of California San Francisco/California Pacific Medical Center), U01-DK083023 ( University of Texas-Southwestern ), U01-DK083020 ( University of Southern California ), U01-DK082992 ( Mayo Clinic ), U01-DK083027 ( Thomas Jefferson / Albert Einstein Medical Center , University of Pennsylvania ), and U01-DK100928 ( Icahn School of Medicine at Mount Sinai ).
Funding Information:
Funding Supported as a Cooperative Agreement by National Institute of Diabetes and Digestive and Kidney Diseases with support from the Intramural Division of the National Cancer Institute, National Institutes of Health, Bethesda, MD (to the Drug-induced Liver Injury Network [https://dilin.dcri.duke.edu/]): U01-DK065176 and U24-DK065176 (Duke University), U01-DK065211 (Indiana University), U01-DK065201 (University of North Carolina), U01-DK065184 (University of Michigan), U01-DK065193 (University of Connecticut), U01-DK065238 (University of California San Francisco/California Pacific Medical Center), U01-DK083023 (University of Texas-Southwestern), U01-DK083020 (University of Southern California), U01-DK082992 (Mayo Clinic), U01-DK083027 (Thomas Jefferson / Albert Einstein Medical Center, University of Pennsylvania), and U01-DK100928 (Icahn School of Medicine at Mount Sinai). Conflicts of interest These authors disclose the following: Dr Bonkovsky has served as a consultant to Alnylam Pharma, Mitsubishi-Tanabe, NA, and Recordati Rare Chemicals, NA, regarding porphyrias; and he serves as principal investigator at Wake Forest University for clinical trials in acute hepatic porphyria, erythropoietic protoporphyria, and primary sclerosing cholangitis, funded by Alnylam, Mitsubishi-Tanabe, and Gilead Sciences, respectively. Dr Durazo has served as a member of the Drug Monitoring Committee of Intercept Pharmaceuticals. Dr Fontana received research support from Gilead Sciences, AbbVie Inc, and Bristol-Myers Squibb and consulting fees from Sanofi-Aventis. Dr Navarro received research grant support from the Patient Centered Outcomes Research Institute and the Albert Einstein Society of the Albert Einstein Medical Center. Dr Phillips has served as a consultant to Biocryst Pharma; she serves as Section Editor for Drug Allergy for UpToDate; and is co-director of IIID Pty Ltd that holds a patent for a method for identification and determination of hypersensitivity of a patient to abacavir. Dr Rockey has received research grants support for his institution from Connatus Pharmaceuticals, Cumberland Pharmaceuticals, Galectin Pharmaceuticals, Genfit, Gilead Sciences, Ironwood Pharmaceuticals, Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, and Sequana Medical and has written chapters for UpToDate. Dr Seeff has served as a member of the Drug Monitoring Committee for Second Genome, Lipocine, Enyo Pharmaceuticals, Intercept Pharmaceuticals, and KPB Pharmaceuticals. Dr Tillman has served as a consultant to Trevena Inc, and his wife is an employee of AbbVie Inc and holds stock in AbbVie Inc, Abbott Laboratories, and Gilead Sciences. Dr Vuppalanchi has received consulting fees for serving on Data Safety Monitoring Boards for Labcorp/Covance, Enyio, and Enanta and also received research grant support to his institution from Gilead Sciences, Zydus Discovery, Cara Therapeutics, and Intercept. The remaining authors disclose no conflicts.
Publisher Copyright:
© 2022
PY - 2022/6
Y1 - 2022/6
N2 - Background & Aims: Garcinia cambogia, either alone or with green tea, is commonly promoted for weight loss. Sporadic cases of liver failure from G cambogia have been reported, but its role in liver injury is controversial. Methods: Among 1418 patients enrolled in the Drug-Induced Liver Injury Network (DILIN) from 2004 to 2018, we identified 22 cases (adjudicated with high confidence) of liver injury from G cambogia either alone (n = 5) or in combination with green tea (n = 16) or Ashwagandha (n = 1). Control groups consisted of 57 patients with liver injury from herbal and dietary supplements (HDS) containing green tea without G cambogia and 103 patients from other HDS. Results: Patients who took G cambogia were between 17 and 54 years, with liver injury arising 13–223 days (median = 51) after the start. One patient died, one required liver transplantation, and 91% were hospitalized. The liver injury was hepatocellular with jaundice. Although the peak values of aminotransferases were significantly higher (2001 ± 1386 U/L) in G cambogia group (P < .018), the median time for improvement in total bilirubin was significantly lower compared with the control groups (10 vs 17 and 13 days; P = .03). The presence of HLA-B∗35:01 allele was significantly higher in the G cambogia containing HDS (55%) compared with patients because of other HDS (19%) (P = .002) and those with acute liver injury from conventional drugs (12%) (P = 2.55 × 10–6). Conclusions: The liver injury caused by G cambogia and green tea is clinically indistinguishable. The possible association with HLA-B∗35:01 allele suggests an immune-mediated mechanism of injury. Clinical Trials.gov number: NCT00345930.
AB - Background & Aims: Garcinia cambogia, either alone or with green tea, is commonly promoted for weight loss. Sporadic cases of liver failure from G cambogia have been reported, but its role in liver injury is controversial. Methods: Among 1418 patients enrolled in the Drug-Induced Liver Injury Network (DILIN) from 2004 to 2018, we identified 22 cases (adjudicated with high confidence) of liver injury from G cambogia either alone (n = 5) or in combination with green tea (n = 16) or Ashwagandha (n = 1). Control groups consisted of 57 patients with liver injury from herbal and dietary supplements (HDS) containing green tea without G cambogia and 103 patients from other HDS. Results: Patients who took G cambogia were between 17 and 54 years, with liver injury arising 13–223 days (median = 51) after the start. One patient died, one required liver transplantation, and 91% were hospitalized. The liver injury was hepatocellular with jaundice. Although the peak values of aminotransferases were significantly higher (2001 ± 1386 U/L) in G cambogia group (P < .018), the median time for improvement in total bilirubin was significantly lower compared with the control groups (10 vs 17 and 13 days; P = .03). The presence of HLA-B∗35:01 allele was significantly higher in the G cambogia containing HDS (55%) compared with patients because of other HDS (19%) (P = .002) and those with acute liver injury from conventional drugs (12%) (P = 2.55 × 10–6). Conclusions: The liver injury caused by G cambogia and green tea is clinically indistinguishable. The possible association with HLA-B∗35:01 allele suggests an immune-mediated mechanism of injury. Clinical Trials.gov number: NCT00345930.
KW - Hepatotoxicity
KW - Herbal and Dietary Supplement
KW - Weight Loss Supplement
UR - http://www.scopus.com/inward/record.url?scp=85128255050&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2021.08.015
DO - 10.1016/j.cgh.2021.08.015
M3 - Article
C2 - 34400337
AN - SCOPUS:85128255050
SN - 1542-3565
VL - 20
SP - e1416-e1425
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 6
ER -